New 'triple pill' could eliminate high blood pressure

A new combination drug may have the potential to revolutionize hypertension treatment worldwide, after a clinical trial has declared it safe to use and very effective.

13 April 2021 | Health

In a recent clinical trial led by researchers from the George Institute for Global Health — with branches in the United Kingdom, Australia, and India — they tested the effectiveness and safety of using an innovative drug for the treatment of high blood pressure, or hypertension.

This drug, nicknamed the “triple pill” by the investigators, combines low doses of three existing drugs for blood pressure.

Namely, these are: telmisartan (20 milligrams), amlodipine (2.5 milligrams), and chlorthalidone (12.5 milligrams).

According to World Health Organization (WHO) data from 2008, about 40 perecentTrusted Source of adults aged over 25 had raised blood pressure worldwide. The WHO also estimate that hypertension is responsible for 7.5 million of all deaths across the globe.

That is because this condition is a major risk factor for both heart disease and stroke, making it a priority to have effective treatments in place for the regulation of blood pressure.

Normally, people with hypertension start taking one blood pressure drug at low doses, only to have to return to their doctors time and again. They then get prescriptions for increasingly higher doses and more hypertension drugs.

According to study co-author Dr. Ruth Webster, “Patients are brought back [to the doctor’s office] at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.”

“The problem with this approach,” she adds, is that it “is not only time inefficient, it’s costly. We also know that many doctors and patients find it too complicated and often don’t stick to the process.”

So, Dr. Webster and colleagues tested a method that, they hoped, would be more efficient, would not have additional side effects, and would remove some of the inconveniences related to a traditional treatment.

This is how they came up with the “triple pill,” which combines fixed low doses of three already existent drugs commonly used to treat hypertension.

‘Triple pill’ vs. traditional therapy

The clinical trial testing the efficacy and safety of the new combination pill took place in Sri Lanka. It involved 700 participants — aged 56, on average — whose average blood pressure amounted to 154/90 millimeters of mercury (mm Hg), which is a typical sign of hypertension.

Of all the participants, some took the combination pill, while others continued to follow their usual blood pressure-lowering therapy, as per their doctors’ advice.

In contrast to those following traditional therapy for hypertension, a larger number of those taking the combination pill were able to lower their blood pressure effectively, reaching their target pressure of 140/90 mm Hg or under.

The target for individuals with diabetes or kidney disease was 130/80 mm Hg, which many people taking the “triple pill” were able to reach.

More specifically, 70 percent of the people taking the “triple pill” achieved their target blood pressure, compared with a little over 50 percent of the participants who continued on traditional hypertension therapy.

In the study paperTrusted Source they published in JAMA, the authors explain that after 6 months from the start of the trial, 83 percent of the people who had started on the “triple pill” were still following this same treatment.

To the contrary, most of the participants following a traditional treatment had added medication or increased drug quantities by the 6-month mark.

“The World Heart Federation [have] set an ambitious goal that by 2025 there will be a 25 percent reduction in blood pressure levels globally,” says study co-author Prof. Anushka Patel.

“The triple pill,” she continues, “could be a low-cost way of helping countries around the world to meet this target.”

Researchers at the George Institute believe that their “triple pill” could really make a difference to current therapy for hypertension.

Right now, the team is looking into the combination drug’s cost effectiveness for various countries and putting into place strategies to make the drug accessible across the world. “This study has global relevance,” says Prof. Patel. – Source: Medicalnewstoday

Similar News

 

Covid numbers alarming

3 hours ago | Health

JEMIMA BEUKES WINDHOEKNamibia’s third Covid-19 wave surges on, with the country recording both its highest death toll – 33 – and...

Otjozondjupa vaccination campaign kicks off

3 hours ago | Health

ESTER KAMATI OTJIWARONGO The Otjozondjupa Region’s Covid-19 vaccination campaign, which started yesterday, is...

Oshakati hospital’s oxygen system broken

1 day - 17 June 2021 | Health

TUYEIMO HAIDULA OSHAKATI Oshakati State Hospital’s oxygen system is not functional, leaving the hospital to depend on cylinders to support patients.With...

Covid: Bodies pile up

1 day - 17 June 2021 | Health

Henriette Lamprecht WINDHOEKBodies of Covid-19 fatalities have spilled over to the state mortuary’s hallways because of a lack of space in refrigerators.According...

Hepatitis E: 8 071 cases, 66 deaths

1 day - 17 June 2021 | Health

Kenya Kambowe RUNDU While Namibia is under siege of the Covid-19 pandemic, the country is also faced with hepatitis E, which...

Angala needed oxygen

1 day - 17 June 2021 | Health

TUYEIMO HAIDULA OSHAKATI Former Oshikoto health director Peter Kefas Angala’s family had to scramble for a hospital bed when his condition began...

Nam surpasses India as infections soar

2 days ago - 16 June 2021 | Health

JEMIMA BEUKES WINDHOEKNamibia is buckling under the heavy weight of daily Covid-19 cases...

Rehoboth gobbles up Ivermectin stock

2 days ago - 16 June 2021 | Health

JEMIMA BEUKES AND OGONE THLAGE WINDHOEKMany residents of Rehoboth, the community hardest hit by Covid-19 after Windhoek, are refusing to report to...

Covid-19: We wasted time, Haufiku says

2 days ago - 16 June 2021 | Health

STAFF REPORTER WINDHOEKFormer health minister Dr Bernard Haufiku, who was relieved of his duties as Special Advisor to the Namibian Presidency on...

Osteoarthritis linked to higher Parkinson's disease risk

3 days ago - 15 June 2021 | Health

A study published in Arthritis Care & Research has uncovered an elevated risk of Parkinson's disease in individuals with osteoarthritis.A retrospective study using Taiwan's Longitudinal...

Latest News

EDITORIAL: The good and bad...

3 hours ago | Opinion

Zambia’s founding president Kenneth Kaunda passed away yesterday – and Namibia owes him a debt of eternal gratitude.Kaunda was a witty politician, revered statesman and...

Green scheme windfall for private...

3 hours ago | Agriculture

OGONE TLHAGE WINDHOEKGovernment is set to offer its green schemes to private-public partners as...

Admin stumbling blocks in Fishrot...

3 hours ago | Justice

Marc Springer WINDHOEKMore than 18 months after their arrest, the 10 people charged in connection with the so-called Fishrot scandal are still...

Otjozondjupa vaccination campaign kicks off

3 hours ago | Health

ESTER KAMATI OTJIWARONGO The Otjozondjupa Region’s Covid-19 vaccination campaign, which started yesterday, is...

It’s comeback season for Magogoz...

3 hours ago | Art and Entertainment

MICHAEL KAYUNDE WINDHOEK After taking some time off as a group to focus...

EES drops second single off...

3 hours ago | Art and Entertainment

STAFF REPORTER WINDHOEK Kwaito artist EES recently dropped his second single of the long-awaited ‘Game Changer’ album. Since the start of...

Olympic deadline looms

3 hours ago | Sports

LIMBA MUPETAMIWINDHOEKThe race to catch the deadline for qualification for the prestigious, multi-sport Olympic Games is on for Namibian athletes.The qualification deadline is 29 June...

How Veteran Mbaeva keeps Arrows...

3 hours ago | Sports

JESSE JACKSON KAURAISAWINDHOEKMaximilian Mbaeva was nowhere to be seen for the major part of the season but still, the team has always been keen to...

!Gawaxab: Economy needs vaccines

1 day - 17 June 2021 | Economics

PHILLEPUS UUSIKU - The successful procurement and expeditious rollout of Covid-19 vaccines in Namibia remain key to the extent and speed of the economic recovery,...

Load More